Abstract:Objectives: The objectives of this study were to examine the degree to which long-term care providers are compliant with product labeling regarding administration of alendronate in patients with renal insufficiency and presence of, or predisposition to, upper gastrointestinal disorders; and to observe differences, if any, in prescribing patterns between alendronate and calcitonin-salmon nasal spray in skilled nursing facilities. Study design: We studied retrospectively analyzed patient charts, including medication histories and laboratory data. Setting: Our study comprised 134 skilled nursing facilities from 21 states. Participants: We studied postmenopausal women, age > or =65 years, receiving either alendronate or calcitonin-salmon nasal spray for a minimum of 2 weeks. Measurements: Consultant pharmacists reviewed resident charts submitted the following data for each resident: 2-week history of alendronate or calcitonin use, 2-week history of H2 receptor antagonist or proton pump inhibitor use, most recently documented serum creatinine, actual body weight, and date of birth. Results: Of 905 subjects in the analysis, 38.5% (n = 348) did not have documentation of serum creatinine. Of the 267 alendronate patients for whom creatinine clearance could be calculated, more than half had renal insufficiencies of creatinine clearance <35 mL/min/1.73 m(2) (51.3%, n = 137). In addition, despite widespread information regarding caution in using alendronate in patients with upper gastrointestinal disorders, we found that 33.9% (n = 151) of all alendronate patients were concurrently receiving either H2 receptor antagonists or proton pump inhibitors. Although similar results were observed in the residents taking calcitonin, that agent has no precautions regarding its use in the renally impaired or in patients with gastrointestinal disorders. Conclusion: Data from this study indicate that long-term care clinicians might not be adequately differentiating patient profiles and safety criteria when initiating residents on osteoporosis pharmacotherapy, as evidenced by similar prescribing trends in both the alendronate and calcitonin groups. Given its package insert's statements regarding use of alendronate in the renally compromised, results from the alendronate group were particularly problematic as a result of the large number of residents with either insufficient renal function or undocumented serum creatinine. These data demonstrate that osteoporosis could be a disease state that should be more closely analyzed through drug utilization reviews and represent yet another opportunity for improved collaboration between medical directors and consultant pharmacists.

Evaluating adherence, tolerability and safety of oral calcium citrate in elderly osteopenic subjects: a real-life non-interventional, prospective, multicenter study

Efficacy and safety of Miacalcic ( salmon calcitonin ) in osteoporotic fracture patients: A 12 weeks,open-label,multicenter,observational study

Effect of supplementation of calcium and vitamin D on bone mineral density and bone mineral content in peri- and post-menopause women; a double-blind, randomized, controlled trial

The Efficacy and Safety of Calcitriol And/or Caltrate D in Elderly Chinese Women with Low Bone Mass

Update on nutrients involved in maintaining healthy bone

An opportunity for medication risk reduction, healthcare provider collaboration, and improved patient care: a retrospective analysis of osteoporosis management

A pilot feasibility randomised controlled trial of bone antiresorptive agents on bone turnover markers in critically ill women

Bisphosphonates and cardiovascular risk in elderly patients with previous cardiovascular disease: a population-based nested case-control study in Italy

Clinical efficacy and outcomes of calcitriol combined with bisphosphonates in the treatment of postmenopausal osteoporosis: A quasi-experimental study

Nutritional therapy of older osteoporotic people with supplemental calcium and vitamin D: side effects, fracture rates, and survival - an internationalised meta-analysis

Safety profile of drugs used in the treatment of osteoporosis: a systematical review of the literature

Effects of an Oral Nutritional Supplementation and Physical Exercise Intervention on Older Adults at Risk for Sarcopenia

Efficacy and safety of ossein-hydroxyapatite complex versus calcium carbonate to prevent bone loss

Oral health indicators and bone mineral density disorders in older age: A systematic review

Anti-fracture efficacy of zoledronate in subgroups of osteopenic postmenopausal women: secondary analysis of a randomized controlled trial

Pro-Osteogenic Effect of the Nutraceutical BlastiMin Complex® in Women with Osteoporosis or Osteopenia: An Open Intervention Clinical Trial

Safety and effects of calcifediol 0.266 milligrams soft capsules monthly and cholecalciferol 25000 international units monthly in osteoporotic women undergoing therapy with alendronate: a cross-sectional study

Potassium citrate prevents increased osteoclastogenesis resulting from acidic conditions: Implication for the treatment of postmenopausal bone loss

A Multicenter, Randomized, Placebo-Controlled Study

Effectiveness of a Novel Food Composed of Leucine, Omega-3 Fatty Acids and Probiotic Lactobacillus paracasei PS23 for the Treatment of Sarcopenia in Elderly Subjects: A 2-Month Randomized Double-Blind Placebo-Controlled Trial

A Multi-Center Observation Study on Medication-Related Osteonecrosis of the Jaw (MRONJ) in Patients with Osteoporosis, and Other Non-Malignant Bone Diseases, in Northwestern Italy over 16 Years